Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...

This is the basis for specialized, AI-powered science search engines such as Consensus and Elicit. Most companies do not ...

Science communication, as a central element of public education ... an out-of-scope manuscript to a more suitable section or ...

Gilead Sciences, Inc. (Nasdaq ... Prevention research presented at HIV Glasgow will also include a systematic review and meta-analysis of real-world data mapping HIV prevalence against PrEP uptake, ...

Jennifer Doudna, the co-developer of CRISPR, says there’s a “coming revolution” in climate-adapted crops and animals.

Under the initial agreement in June 2023, AbTherx received worldwide rights to Atlas Mice, a suite of transgenic mouse technologies acquired by Gilead, and committed to a multi-year, multi-target ...

UK High Court judge unconvinced by Pfizer that uniQure’s patent is invalid | Companies in dispute over patents covering ...

Here is set in one location — a piece of land in Pennsylvania — and seen through the perspective of a fixed camera over the course of more than 100 years. The relentless passage of time and ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its groundbreaking work in antiviral therapies. Valued at a market cap of $ ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price target at $84.00. Terence Flynn’s rating is based on ...